<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>About • MultiOmics Inc.</title>

  <!-- SEO -->
  <meta name="description" content="Learn about MultiOmics Inc., the team behind LiquidMammo™, a microRNA-based liquid biopsy designed to complement imaging for early breast cancer detection." />
  <meta name="keywords" content="MultiOmics, LiquidMammo, microRNA screening, liquid biopsy, early detection, biotech, clinical diagnostics, breast cancer screening" />

  <!-- Stylesheet -->
  assets/css/styles.css
</head>

<body>

<!-- =========================
     HEADER
========================== -->
<header>
  <div class="container">
    <nav>
      <div class="brand">
        assets/logos/liquidmammo-logo.png
        <strong>LiquidMammo™</strong>
      </div>
      <div class="nav-links">
        index.htmlHome</a>
        how-it-works.htmlHow It Works</a>
        science.htmlScience</a>
        evidence.htmlEvidence</a>
        patients.htmlPatients</a>
        clinicians.htmlClinicians</a>
        biobank.htmlBiobank</a>
        pricing.htmlPricing</a>
        contact.htmlContact</a>
        privacy.htmlPrivacy</a>
      </div>
    </nav>
  </div>
</header>


<!-- =========================
     HERO
========================== -->
<section class="hero-tight">
  <div class="container grid grid-2">

    <div>
      <span class="eyebrow">About MultiOmics Inc.</span>
      <h1>Advancing earlier, more equitable breast cancer detection</h1>
      <p class="small">
        MultiOmics Inc. develops LiquidMammo™, a microRNA‑based liquid biopsy designed to complement imaging in breast cancer screening.
      </p>
    </div>

    <div>
      https://images.unsplash.com/photo-1581091012184-5c38a6f519f5?auto=format&fit=crop&w=1200&q=80
    </div>

  </div>
</section>


<!-- =========================
     WHO WE ARE
========================== -->
<section class="section">
  <div class="container grid grid-3">

    <div class="card">
      <h3>Who we are</h3>
      <p class="small">
        MultiOmics Inc. is a molecular diagnostics company focused on translating circulating microRNA biology into practical tools for earlier disease detection. The team spans molecular biology, biostatistics, clinical diagnostics, and population screening.
      </p>
    </div>

    <div class="card">
      <h3>Our mission</h3>
      <p class="small">
        We aim to improve breast cancer screening performance by complementing imaging with biologically‑driven signals — especially in populations where mammography alone underperforms.
      </p>
    </div>

    <div class="card">
      <h3>Where we operate</h3>
      <p class="small">
        MultiOmics Inc. is headquartered in Washington, DC, and operates out of LabCentral, Cambridge, MA — a premier innovation ecosystem associated with MIT and biotech venture creation.
      </p>
    </div>

  </div>
</section>


<!-- =========================
     SCIENCE & TECHNOLOGY
========================== -->
<section class="panel-light section">
  <div class="container">

    <h2>The science behind LiquidMammo™</h2>

    <div class="grid grid-3">

      <div class="card">
        <h3>microRNA biology</h3>
        <p class="small">
          LiquidMammo™ analyzes dysregulation patterns in circulating microRNAs — small, non‑coding RNA molecules associated with tumor biology — to detect early molecular changes that may precede imaging findings.
        </p>
      </div>

      <div class="card">
        <h3>Multi‑marker panel</h3>
        <p class="small">
          The proprietary panel integrates signals across multiple microRNA markers to increase robustness, reproducibility, and performance across heterogeneous patient groups.
        </p>
      </div>

      <div class="card">
        <h3>Clinical rationale</h3>
        <p class="small">
          By layering molecular data with imaging, clinicians can contextualize findings, reduce uncertainty, and support earlier action in women with dense breasts and those with equivocal imaging results.
        </p>
      </div>

    </div>

  </div>
</section>


<!-- =========================
     TEAM & ADVISORS (SAFE PLACEHOLDERS)
========================== -->
<section class="section">
  <div class="container">

    <h2>Leadership & scientific advisors</h2>

    <div class="grid grid-3">

      <div class="card">
        <h3>Founding team</h3>
        <p class="small">
          <!-- Replace once approved for public use -->
          The founding team combines expertise in molecular diagnostics, clinical assay development, epidemiology, and biostatistics.
        </p>
      </div>

      <div class="card">
        <h3>Clinical advisors</h3>
        <p class="small">
          <!-- Replace once approved for public use -->
          A network of breast imaging radiologists and oncology specialists inform assay design, clinical interpretation, and implementation strategy.
        </p>
      </div>

      <div class="card">
        <h3>Academic collaborations</h3>
        <p class="small">
          <!-- Replace with verified program details -->
          MultiOmics collaborates with leading academic clinicians to validate assay performance and evaluate real‑world utility.
        </p>
      </div>

    </div>
  </div>
</section>


<!-- =========================
     IMPACT & OPPORTUNITY
========================== -->
<section class="panel-light section">
  <div class="container grid grid-3">

    <div class="card">
      <h3>Impact for patients</h3>
      <p class="small">
        A non‑invasive tool that can help clarify equivocal imaging, reduce false positives, and support earlier detection in dense‑breast populations.
      </p>
    </div>

    <div class="card">
      <h3>Impact for clinicians</h3>
      <p class="small">
        Standardized, biologically‑based insights that integrate seamlessly into screening workflows without requiring additional procedures.
      </p>
    </div>

    <div class="card">
      <h3>Business opportunity</h3>
      <p class="small">
        Growing demand for liquid biopsy tools in early detection, payer interest in reducing long‑term screening costs, and a scalable CLIA LDT commercialization path.
      </p>
    </div>

  </div>
</section>


<!-- =========================
     FOOTER
========================== -->
<footer>
  <div class="container footer-grid">

    <div>
      <strong>LiquidMammo™</strong><br>
      A test developed by MultiOmics Inc.
      <p class="footer-note">
        MultiOmics Inc. is headquartered in Washington, DC, and operates at LabCentral, Cambridge, MA.
      </p>
    </div>

    <div class="footer-logo">
      assets/logos/multiomics-logo.png
      <div class="footer-note" style="line-height:1.2">
        Developed by<br>MultiOmics Inc.
      </div>
    </div>

  </div>

  <div class="container footer-note" style="margin-top:20px;">
    © <script>document.write(new Date().getFullYear())</script> MultiOmics Inc. •
    privacy.htmlPrivacy & Compliance</a> •
    contact.htmlOrder / Kits</a>
  </div>
</footer>

</body>
</html>